There was no survival benefit for atezolizumab in the patients with ≥5% tumor-infiltrating immune cells positive for PD-L1 (primary endpoint) with a mOS of 11.1 months versus 10.6 months (HR 0.87; 95% CI, 0.63–1.21; p = 0.41) [62]. This evidence concerns the gene CD274 and neoplasm.